Bio-Rad Laboratories, Inc. (BIO) FCF Payout Ratio: N/A
The FCF payout ratio for Bio-Rad Laboratories, Inc. (BIO) is N/A.
BIO FCF Payout Ratio Metrics
FCF PAYOUT RATIO
N/A
Payout Ratio Comparison
FCF Payout Ratio
N/A
Earnings Payout Ratio
N/A
Dividend Yield
N/A
FCF Yield
4.46%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $374.60M | $0 | 0.0% |
| 2024 | $266.20M | $0 | 0.0% |
| 2023 | $218.26M | $0 | 0.0% |
| 2022 | $80.29M | $0 | 0.0% |
| 2021 | $535.72M | $0 | 0.0% |
| 2020 | $476.41M | $0 | 0.0% |
| 2019 | $359.37M | $0 | 0.0% |
| 2018 | $155.67M | $0 | 0.0% |
| 2017 | ($10.99M) | $0 | N/A (Loss) |
| 2016 | $74.50M | $0 | 0.0% |
| 2015 | $72.84M | $0 | 0.0% |
| 2014 | $136.83M | $0 | 0.0% |
| 2013 | $61.78M | $0 | 0.0% |
| 2012 | $121.83M | $0 | 0.0% |
| 2011 | $159.41M | $0 | 0.0% |
| 2010 | $133.38M | $0 | 0.0% |
| 2009 | $248.71M | $0 | 0.0% |
| 2008 | $102.56M | $0 | 0.0% |
| 2007 | $128.91M | $0 | 0.0% |
| 2006 | $65.24M | $0 | 0.0% |
| 2005 | $72.23M | $0 | 0.0% |
| 2004 | $62.60M | $0 | 0.0% |
| 2003 | $58.64M | $0 | 0.0% |
| 2002 | $63.53M | $0 | 0.0% |
| 2001 | $56.27M | $0 | 0.0% |
| 2000 | ($7.16M) | $0 | N/A (Loss) |
| 1999 | ($185.10M) | $0 | N/A (Loss) |
| 1998 | $6.10M | $0 | 0.0% |
| 1997 | ($33.70M) | $0 | N/A (Loss) |
| 1996 | $18.00M | $0 | 0.0% |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
Bio-Rad Laboratories, Inc. FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz